Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ME-401

Phase 2Small molecule

Kyowa Kirin Co., Ltd.

1

Indications

4

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Indolent B-Cell Non-Hodgkin's LymphomaActive, not recruiting

Indolent B-Cell Non-Hodgkin's LymphomaPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q2 2028

Phase 2Active, not recruiting

Indolent B-Cell Non-Hodgkin's Lymphoma

NCT04533581

Clinical

Trials by Indication[1]

Lymphoma2 trials

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Terminated·MMEI Pharma, Inc.·Phase 1·NCT02914938·97 enrolled

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Completed· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 1·NCT03985189·14 enrolled

Diffuse Large B-Cell Lymphoma1 trial

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated·DDeepa Jagadeesh·Phase 1/2·NCT04517435·13 enrolled

Indolent B-cell Non-Hodgkin's Lymphoma1 trial

A Japanese Phase 2 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

Active, not recruiting· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 2·NCT04533581·61 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ME-401. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ME-401 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ME-401. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kyowa Kirin Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Kyowa Kirin Co., Ltd.

Related News